Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$1.96M, compared with -$5.05M a year earlier. Trailing-twelve-month operating income was -$4.73M.
Context
- Operating income grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -79.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.96M-114.9% QoQ
- Last fiscal yearDec 2025
- -$7.82M-79.7% YoY
- LTMMar 2026
- -$4.73M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +61.2% | +100.0% | +38.8 pp |
| 1 year | -79.7% | +100.0% | +179.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (7.82M) USD
- Year-over-year change
- -79.7%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.82M) | -79.7% |
| FY2024 | 2024-12-31 | (4.35M) | -15.1% |
| FY2023 | 2023-12-31 | (3.78M) | — |
Operating Income vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's LTM Mar 2026 operating income of -$4.73M is the highest of the 8 companies compared; the peer median is -$80.77M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
PLYXPolaryx Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$4.73M | — | — | — |
| LTM Mar 2026 | -$37.12M | +25.8% | — | — | |
| LTM Mar 2026 | -$43.68M | -484.7% | — | 157.7% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$47.63M | +33.8% | — | — |
| LTM Mar 2026 | -$80.77M | +17.1% | — | 286.2% | |
| LTM Mar 2026 | -$133.6M | -162.4% | — | — | |
| LTM Mar 2026 | -$163.14M | -207.8% | — | 1372.9% | |
| LTM Mar 2026 | -$191.86M | +46.8% | — | 618909.7% | |
| Peer median (excluding PLYX) | -$80.77M | +17.1% | — | 829.5% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 2.77M | 2.81M | 6.27M |
| Selling, General & Admin | 1.01M | 1.54M | 1.56M |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | (3.78M) | (30.36M) | (8.99M) |
| EBITDA Margin | — | — | — |
| Operating Income | (3.78M) | (4.35M) | (7.82M) |
| Operating Margin | — | — | — |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2K | (26M) | (1.16M) |
| Income Before Tax | (3.78M) | (30.36M) | (8.99M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.02) | (0.16) | (0.19) |
| EPS (Diluted) | (0.02) | (0.16) | (0.19) |
| Weighted Avg Shares | 189.37M | 189.37M | 47.34M |
| Weighted Avg Shares (Diluted) | 189.37M | 189.37M | 47.34M |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.